Related Experiment Video
Updated: Mar 24, 2026

Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Dual Antiplatelet Therapy Duration: A Review of Current Available Evidence
Ioannis Mastoris1, Priyanka Maria Mathias2, George D Dangas3
1Icahn School of Medicine, Mount Sinai Hospital, New York, New York; Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York.
Insights
The optimal duration of dual-antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) is not definitively established. Individual patient factors and clinical judgment are crucial for determining DAPT treatment length.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pharmacology
Background:
- Dual-antiplatelet therapy (DAPT) is standard after percutaneous coronary intervention (PCI) to prevent thrombotic events.
- Optimal DAPT duration following PCI remains an area of active research and clinical debate.
Purpose of the Study:
- To review randomized clinical trials (RCTs), pooled analyses, and meta-analyses on DAPT duration after PCI.
- To provide recommendations for optimal DAPT duration based on patient and procedural profiles.
Main Methods:
- Extensive literature search across multiple databases (MEDLINE, Scopus, Cochrane Library).
- Inclusion of RCTs, meta-analyses, and observational studies without language or date restrictions.
- Exclusion of irrelevant studies not pertaining to DAPT duration after PCI.
Main Results:
- Identified 10 RCTs comparing DAPT durations and 3 meta-analyses.
- Numerous observational studies provided additional insights into DAPT duration.
- No conclusive evidence was found to mandate a specific DAPT duration post-PCI.
Conclusions:
- No definitive evidence dictates mandatory DAPT duration after PCI.
- Specific patient groups (e.g., diabetics, those on anticoagulation) require tailored DAPT regimens.
- Individualized clinical judgment considering patient, procedural, and stent-related factors is essential.
Purpose:
Multiple regimens of antiplatelet and anticoagulation therapy have been used in the past in patients undergoing percutaneous coronary intervention (PCI). Later trials of PCI stenting demonstrated the efficacy of dual-antiplatelet therapy (DAPT) in reducing stent- and non-stent-related thrombotic events in this specific population. Nonetheless, the required duration of DAPT has not yet been elucidated. In this article we sought to identify various randomized clinical trials (RCTs), pooled analyses, meta-analyses, and data pertaining to the optimal duration of DAPT and attempt some recommendations based on patients' clinical and procedural profiles.
Methods:
We performed an extensive search using MEDLINE, Scopus, Cochrane Library, and Internet sources for abstracts, manuscripts, and conference reports without any language or date restrictions. In our review we included all available evidence from RCTs, meta-analyses, observational studies, and abstracts pertaining to our topic. Search results that were deemed irrelevant or that would not serve the goal or topic of our review were excluded.
Results:
Our search yielded 10 RCTs directly comparing different durations of DAPT, 3 meta-analyses amassing the evidence resulting from randomized data, and numerous observational studies that served the aim of our review. The observational studies included in the manuscript are directly related to instances in which RCTs could not be performed or introduce important concepts related to the duration of DAPT.
Implications:
There is no conclusive evidence that determines the mandatory DAPT duration after PCI. In addition, there are distinct patient populations that need specific treatment regimens, such as diabetic patients or those on long-term oral anticoagulation. Therefore, clinical judgement and meticulous examination of all pertaining risk factors are required for each individual. These factors include those related to a patient's characteristics, treatment procedures, lesion complexity, and stent type. Currently ongoing studies are anticipated to further elucidate and integrate our understanding with regard to DAPT.
More Related Videos
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Peripheral Artery Disease III: Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration

